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Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be
the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of
treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be
beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic
control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary
ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been
conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with
placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still
unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical
practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and
hypertension) but also the possible effects on established cardiovascular disease.
1. Introduction
Diabetes mellitus (DM) is a chronic disease, the worldwide
prevalence of which is high and continually growing. It is
associated with high morbidity and mortality and is one of
the diseases with the greatest impact on public health.
Between 1990 and 2010, the number of adults diagnosed with
diabetes in the United States tripled, from 6.5 million to 20.7
million, while the total population increased by only 27%
(from 178million to 226 million). The International Diabetes
Federation calculated that, in 2015, one in every 11 adults had
diabetes (415million individuals) and estimated that by 2040,
the prevalence would be one every 10 (642 million individ-
uals) [1]. The American Diabetes Association (ADA) reports
that if the current epidemiological trend continues, by 2050
one in three American adults could have DM [2].
In Spain, the results of the largest epidemiological study
ever conducted in the country were published in 2012,
Di@bet.es. It revealed that 13.8% of Spaniards (5.3 million
individuals) over the age of 18 had type 2 diabetes (T2DM).
Of these, almost 3 million had been diagnosed, but 2.3
million—43% of the total—were unaware that they had the
disease [3].
DM is not only prevalent; it is a complex chronic dis-
ease. It is very closely related to the presence of comorbid-
ities and chronic complications that can be macrovascular,
microvascular, or mixed. Macrovascular complications
include cerebral and peripheral vascular disease and car-
diovascular disease. Microvascular complications include
diabetic retinopathy, neuropathy, and nephropathy. Mixed
complications are also common such as diabetic foot and
erectile dysfunction.
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Descriptive studies have noted a gradual decline in
complications these recent years. This probably reflects
the advances in acute clinical care and improvement in
national health services and health education in individ-
uals with diabetes. Nevertheless, cardiovascular disease
continues to be the main complication and cause of death
in the diabetic patient [4]. Heart failure, with an estimated
prevalence of 5%, is also considered a health problem of
first order in Spain, despite a lack of proper studies to
correctly estimate its impact. It is the main cause of hospi-
talisation in adults over 65 years and accounts for 3% of
hospital admissions and 3.5% of healthcare costs. In
2010, heart failure was responsible for 3% of all deaths
in men and in 10% in women [5].
2. Cardiovascular Disease and Diabetes
The increase in cardiovascular disease (CVD) in patients
with DM was already apparent in the Framingham (1979)
[6] andMERIT (1993) clinical trials [7], which suggested that
diabetic patients have a two- to fourfold risk of CVD com-
pared to nondiabetic patients. Moreover, CVD in patients
with DM is three times more likely to have a fatal outcome
compared to the normal population.
Now that the false concept of equivalence of diabetes and
CVD has been overcome, it is important to bear in mind the
concept of vascular continuum introduced by Dzau et al. in
1991. The concept of vascular continuum describes the inex-
orable progression of CVD from the presence of risk factors
to the development of myocardial infarction, left ventricular
hypertrophy, and cardiovascular death. This concept has
been changing over the years, especially as a result of accep-
tance of the effects of the renin-angiotensin-aldosterone
system (RAAS), introducing the notion of the cardiorenal
continuum. Furthermore, the boundary between macro-
and microvascular complications is becoming blurred due
to a better understanding of the molecular pathogenic
mechanisms of DM [8].
A diabetic patient can be found on very different parts of
the CVD spectrum. He may be newly diagnosed or present
more advanced disease and have suspected silent CVD or
may be progressing towards the terminal stages of a cardio-
vascular disease. In all these cases with the accompanying
constellation of other cardiovascular risk factors (CVRF)
(hypertension [HT], smoking, obesity, dyslipidaemia, and
so on) [9, 10].
The choice of treatment in a patient with T2DM is
complex, not only because of the large therapeutic arsenal
currently available but also the multitude of circumstances
that must be assessed when selecting the right treatment
(efficacy, weight loss, risk status or CVD, side effects, costs,
hypoglycaemias, etc.). In addition, CVD and the safety of
treatments for T2DM have achieved special prominence
in recent years. On 21 May 2007, cardiologist Steve Nissen
published a meta-analysis suggesting that, compared to a
control group, rosiglitazone treatment showed a statistically
significantly higher risk of myocardial infarction and an
increase in mortality close to statistical significance. Since
rosiglitazone was withdrawn in 2010 due to this potentially
harmful cardiovascular effect, studies must now demonstrate
cardiovascular safety in all new drugs for the treatment of
T2DM [11].
Among all the drugs available, the compounds known as
glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
appear to be not just innocuous in terms of CVD but indeed
to be beneficial.
3. Incretins: Glucagon-Like Peptide-1 (Glp-1)
The concept of the incretin hormone system and its relation-
ship with DM dates from the 1970s [12]. The incretins are
hormones secreted by cells in the midgut that potentiate
glucose-dependent insulin secretion [13].
GLP-1 (GLP-1 7-36) is secreted continuously in both
interprandial and prandial periods. Primary biological
actions described for intact GLP-1 are mediated by the
GLP-1 receptor (GLP-1R). GLP-1 (9-36) metabolite which
appears after dipeptidyl-peptidase 4 (DPP-4) action also
exhibits its own biological actions [13].
The biological action of native GLP-1 (7-36) and its
metabolites GLP-1 (9-36) and GLP-1 (28-36) is under study,
as it seems that these metabolites could exhibit their own bio-
logical actions independent of those mediated via GLP-1R.
The actions exerted by GLP-1 through GLP-1R are the best
known and are affected in numerous areas as a result of the
wide distribution of GLP-1R in the body [14, 15].
These actions include
(1) GLP-1 increases glucose-dependent insulin synthesis
and secretion in the pancreatic islets. In animal stud-
ies, they show an increase or maintenance of the beta-
cell mass. It also decreases glucagon secretion by act-
ing on the alpha cells.
(2) GLP-1 acts as a neurotransmitter and can act on both
the CNS (satiety and loss appetite) and peripheral
nervous system (PNS).
(3) GLP-1 delays gastric emptying and inhibits pentagas-
trin and acid secretion stimulated by food ingestion.
(4) GLP-1 has cardiovascular benefits on blood pressure,
the vascular endothelium, atherosclerosis progression
and inflammation, myocardial ischaemia, heart fail-
ure, and so on, which will be discussed in detail below.
4. Degradation-Resistant Glp-1 Ras
Multiple GLP-1 RAs have been developed for the treatment
of T2DM (Table 1) [10]. New GLP-1 RAs are currently being
developed, and some are in very advanced phases (e.g., sema-
glutide and ITCA 650) (Table 1).
5. Beneficial Effects of Glp-1 Analogues on
Cardiovascular Risk Factors in Patients with
Type 2 Diabetes
5.1. Glycaemic Control. Although glycaemic control is associ-
ated with reductions in the risk of microvascular
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complications, the benefits of strict glucose control on
macrovascular complications are more questionable. It seems
reasonable to think after the VADT, ACCORD, and
ADVANCE studies that intensive treatments in patients with
established cardiovascular disease failed to show a reduction
in cardiovascular episodes. Nevertheless, it should be taken
into account that the patients selected in these trials were
high cardiovascular risk. In contrast, the UKPDS study
showed that patients whose treatment began intensively at
diagnosis presented a lower incidence of cardiovascular epi-
sodes, even at 10 years, when the HbA1c levels for both
groups were similar. This arose the concept of “glycaemic
legacy,” which was expanded to the concept of “metabolic
legacy” following the STENO 2 trial. It therefore seems clear
that the intensive treatment of glycaemia along with other
metabolic abnormalities in the early stages of the disease
produces a benefit on macrovascular complications that is
maintained in the long term [16].
All GLP-1 RAs currently approved for the treatment of
T2DM are administered subcutaneously. Depending on their
pharmacokinetic properties, they will be administered daily
or weekly.
Short-acting GLP-1 RAs (daily exenatide and lixisena-
tide) are administered in relation to meals. These exhibit
large fluctuations in their plasma concentrations, resulting
in intermittent activation of GLP-1 RAs, producing a modest
effect on both glucose levels between doses and fasting
plasma glucose and HbA1c control. Exenatide 10μg twice
daily experiences a drop in HbA1c. Exenatide 10μg experi-
ences a drop in HbA1c of −0.78% and the 5μg a drop of
−0.4%, both significant against placebo [17, 18]. On the other
hand, lixisenatide decreases A1c in about −0.32%. However,
they show a higher capacity for delaying gastric emptying
and, therefore, greater efficacy in reducing postprandial glu-
cose levels. Lixisenatide showed a better reduction in post-
prandial blood glucose compared to liraglutide which had a
better reduction in fasting blood glucose, which is not sur-
prising considering their half-lives.
Long-acting agonists were developed to prolong their
action on the GLP-1R and consequently their pharmacody-
namic action. They are administered daily (liraglutide) or
weekly (exenatide-LAR, albiglutide, and dulaglutide). In
head-to-head studies, they show better efficacy in reducing
fasting plasma glucose and HbA1c control compared to
short-acting drugs. The DURATION-1 study compared the
efficacy of exenatide twice daily with a weekly dose. At the
end of the study, both treatment arms showed a clear
improvement in HbA1c values: 1.9% for the long-acting
compared to −1.5% of the short-acting agonist (p = 0 0023).
The LEAD-6 study compared treatment with liraglutide
(1.8mg/day with dose escalation) versus exenatide
(10μg/12 hours with dose titration) [19]. After a 26-week fol-
low-up, liraglutide showed a reduction of −1.2%, compared
to −0.79%. In the AWARD-1 study, dulaglutide was superior
to twice-daily exenatide (−1.51% for dulaglutide 1.5mg/
week, −1.30% for dulaglutide 0.75mg/week, and −0.99 for
twice-daily exenatide) [20]. But, due to tachyphylaxis, they
do not exert as much effect on the gastric emptying that
affects postprandial glycaemic control.
In summary, with respect to glycaemic control, long-
acting agonists are more effective in reducing A1c than
short-acting. Within long-acting agonists and glycaemic con-
trol, liraglutide 1.8mg has not been statistically significantly
surpassed by any GLP-1 RA in head-to-head comparisons
carried out to date.
It is important to note that, in addition to glycaemic con-
trol, glycaemic variability is a factor that has sometimes been
related with a higher risk of CVD due to increased oxidative
stress [21, 22]. Studies with GLP-1 RAs to date have not
included this measurement. However, in the 52-week exten-
sion trial dual action of liraglutide and insulin degludec in
type 2 diabetes (DUAL I), the authors studied the fluctua-
tions in plasma glucose of the combination of insulin deglu-
dec and liraglutide (IDegLira) against each of its components
separately. A significantly lower number of fluctuations were
observed in the interstitial glucose with IDegLira, compared
to insulin degludec alone. Furthermore, the liraglutide treat-
ment arm behaved similarly—as regards variability—to the
cohort with insulin degludec alone [23]. Glycaemic variabil-
ity should undoubtedly be a field to explore in trials with
GLP-1 analogues, due to its possible impact on cardiovascu-
lar morbidity.
5.2. Arterial Hypertension. Arterial hypertension (HT) is a
very common complication in patients with T2DM. It affects
79.4% of diabetic adults in Spain, according to the Di@bet.es
study [24]. Excess weight and obesity, insulin resistance, and
hyperglycaemia itself are the main factors associated with its
greater presence.
The combination of poor blood pressure (BP) control
together with poor glycaemic control considerably increases
the risk of developing a myocardial infarction, heart failure,
or stroke. According to the UKPDS study, a reduction in sys-
tolic blood pressure (SBP) of 10mmHg results in a 15%
reduction in mortality in patients with T2DM. In the
ADVANCE study, a reduction of 5.6mmHg reduced the risk
of cardiovascular death by 18%. The HOPE study also
showed that a reduction of 2.5mmHg, with or without a
1mmHg reduction in diastolic blood pressure (DBP), may
reduce the risk of myocardial infarction, stroke, or cardiovas-
cular death by 25% [25].
Clinical trial data so far seems to significantly conclude
that treatment with GLP-1 analogues reduces BP values.
The mechanism by which this reduction occurs has not yet
been clearly identified but may be due to complex regulation.
In fact, effects occur early—two weeks after the start of
Table 1: GLP-1 RAs.
GLP 1 RAs Brand name Administration Action
Exenatide Byetta® Twice daily Short acting
Exenatide-LAR Bydureon® Once weekly Long acting
Lixisenatide Lyxumia® Once daily Short acting
Liraglutide Victoza® Once daily Long acting
Albiglutide Eperzan® Once weekly Long acting
Dulaglutide Trulicity® Once weekly Long acting
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treatment—suggesting that it is a decrease independent of
weight loss and that other mechanisms may be involved.
One potential mechanism could be direct activation of the
GLP-1R in arteries and the renal system, including an
improvement in endothelial function, as well as a vasodilator
and natriuretic effect by inhibition of the RAAS. However,
other mechanisms could be independent of GLP-1R, for
example, the activation of nitric oxide by cyclic GMP [25].
None of the trials conducted to date has been specially
designed to evaluate the effects of GLP-1 RAs on BP. Nev-
ertheless, several reviews and meta-analyses seem to agree
that both exenatide and liraglutide produce a mean
decrease of −1 to −5mmHg compared with placebo and
other active comparators [25]. In the DURATION trials,
weekly exenatide showed a mean reduction in BP of −3
to −5mmHg. Moreover, in clinical trials with exenatide,
twice-daily dosing also resulted in a significant decrease
in SBP compared with placebo (−2.8mmHg) or insulin
(−0.37mmHg), with larger decreases in those patients
who started with SBP> 150mmHg [26]. In the LEAD
studies, liraglutide caused a decrease in SBP of between
−2.7 and− 6.6mmHg [19, 25, 27]. It is important to
remember that GLP-1 RAs do not reduce BP in normo-
tensive subjects.
Furthermore, GLP-1 RA treatment is also known to be
associated with a slight increase in heart rate, generating a
mean increase of +1.86 beats per minute (bpm) compared
with placebo and + 1.90 bpm with active comparator. These
increases are more evident with liraglutide and extended-
release exenatide [28]. The mechanism for this could be
related to vagal depression, insulin-mediated activation of
the sympathetic system, and the large increase in insulin after
the infusion of GLP-1. Although drugs that reduce heart rate
have been shown to reduce cardiovascular risk, no harmful
effect of this increased rate has been observed with GLP-1
agonists to date.
5.3. Dyslipidaemia. Given the insulin resistance and meta-
bolic disorder in patients with T2DM, dyslipidaemia is an
important and common comorbidity. The typical lipid pro-
file of a T2DM patient, known as atherogenic dyslipidaemia,
includes a decrease in HDL cholesterol (HDL-C) and an
increase in LDL cholesterol (LDL-C), total cholesterol, and
triglycerides. The combination of dyslipidaemia and poor
glycaemic control plays an essential role in the development
of atherosclerosis [29]. According to the Quebec Cardiovas-
cular Study, the combination of diabetes, high LDL-C, and
high apolipoprotein B confers a 20-fold risk of developing
cardiovascular episodes [30].
It is interesting to note that several clinical trials with
GLP-1 RAs have described an improved lipid profile due to
as yet unknown mechanisms. No clinical trials have been
conducted that evaluate the different doses and impact on
lipid profiles of each GLP-1 RA. Additionally, most trials
were not specifically designed to look at the effect of GLP-1
RAs on lipid profile. The majority are head-to-head trials in
which the GLP-1 agonist is compared to placebo or other
treatments, such as an active comparator, mainly exenatide
and liraglutide.
Exenatide in both twice-daily doses of 5μg and 10μg and
in the extended-release formulation and liraglutide 1.8mg
have shown a reduction in total cholesterol levels. The lower-
ing effect seems more marked with extended-release exena-
tide and liraglutide 1.8mg. In terms of lowering triglyceride
values, liraglutide (1.2mg and 1.8mg) has been found to be
more effective [29].
In a meta-analysis of the LEAD trials (liraglutide clinical
development program), it was observed that, in all of them,
treatment with liraglutide reduced LDL-C (−7.73mg/dL),
total cholesterol (−5.03mg/dL), and triglycerides, compared
with standard treatment. The LEAD-6 study found a reduc-
tion in triglycerides of −15.7mg/dL, compared with twice-
daily exenatide. Moreover, decreases in HDL-C were
observed, except in patients on combined treatment with
TZD [31].
In the DURATION studies (with extended-release exena-
tide), reductions of between 4.64 and 34.8mg/dL were found
in total cholesterol compared with standard treatment. These
reductions were much greater than with twice-daily exena-
tide. No changes were observed in HDL-C levels [29].
In a 3-year follow-up trial that compared twice-daily exe-
natide with placebo, the group treated with exenatide were
found to have reductions of −6% in LDL-C values, −5% in
total cholesterol, and− 12% in triglycerides [32]. Another
study, the EUREXA trial, also showed reductions in triglycer-
ides and improvement in HDL-C with twice-daily exenatide
compared to glimepiride [33, 34].
A modest improvement in the lipid profile of a patient
with T2DM can produce a significant impact from a clinical
point of view; nevertheless, the mechanism has not been
clearly identified. One possible explanation could be
improved glycaemic control, which would reduce insulin
resistance and hepatic triglyceride synthesis. Another possi-
ble action could be mediated by GLP-1R in the intestinal
mucosa, resulting in reduced secretion of apolipoprotein
B48, present in the chylomicrons, with a consequent reduc-
tion in plasma triglycerides. The beneficial effects of liraglu-
tide could be related to modulation of the expression of
certain genes related to lipid and glucose metabolism [35].
Furthermore, in studies performed with exenatide, this agent
was seen to suppress the production of intestinal lipoproteins
by acting directly on their synthesis, independently of
changes in weight, satiety, or gastric emptying [29]. It is
important that new trials should be carried out that include
all GLP-1 agonists and their effect on the lipid profile as the
primary objective and that they explore the mechanism by
which this improvement occurs.
5.4. Weight. Obesity contributes to the development of both
T2DM and CVD.Modest weight losses of 5%–10% have been
found to contribute to changes in glycaemic control, number
of medications for controlling CVRFs, the patient’s func-
tional activity, and their quality of life. GLP-1 RAs have been
shown to improve glycaemic control with an added beneficial
effect on weight. Mean weight loss has been estimated at
between 0.4 and 5.1 kg. However, this improvement in
weight varies between GLP-1 RAs and between individuals,
although up to 30% of patients do not lose weight [36].
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In the analysis performed in the AMIGO trials,
patients on twice-daily exenatide presented a weight loss
of between 4 and 4.4 kg after 82 weeks when added to
SU [37, 38]; the impact of exenatide on weight was main-
tained for 3 years (−5.3 kg) [32]. In the DURATION-2
trial, weekly exenatide produced significant weight loss
(−2.3 kg) within 26 weeks [39].
In the LEAD trials, liraglutide resulted in a weight loss of
between 1 and 3.2 kg in 26–52 weeks when it was used alone
or added to metformin or metformin plus rosiglitazone. The
weight loss observed with liraglutide was dose-dependent
[40–43]. In the SCALE trial, high doses of liraglutide 3mg
resulted in a weight loss of 8.4 kg (8% of weight) at 56 weeks
compared with placebo [44].
Lixisenatide (Get Goal Study) showed no significant
weight losses compared with placebo when it was used alone
or added to metformin or pioglitazone. It did, however, pro-
vide a discrete reduction in weight when added to SU
(−1.76 kg) [45–47].
Dulaglutide resulted in a weight loss of −1.4 to −3 kg
when it was used alone or added to metformin (AWARD-
3). The weight loss with dulaglutide was similar to that of
metformin when both were used alone and greater than sita-
gliptin when added to metformin (AWARD-5) [48, 49].
In the HARMONY studies, albiglutide was found to be
neutral in terms of weight, both when compared with placebo
and when added to metformin, metformin+ glimepiride or
metformin+pioglitazone (HARMONY 1, 3, and 5) [50–52].
There are few studies comparing the effects of the
GLP-1 RAs on weight loss. These data should be com-
pared with caution, due to the heterogeneity of the popu-
lations studied and the different treatment combinations
used. In summary, liraglutide 1.8mg results in greater
weight loss compared with the other GLP-1 RAs. System-
atic reviews and meta-analyses of GLP-1 RAs that have
included studies on liraglutide (1.2 and 1.8) and exenatide
(daily and weekly) have demonstrated weight loss but have
been unable to show a significant difference between the
agents and different doses. However, head-to-head trials
seem to show that lixisenatide and albiglutide have a
weaker effect on weight loss [36].
6. Other Possible Benefits in Cardiovascular
Risk Factors
6.1. Glp-1 and Endothelial Function. Endothelial dysfunction
is a pathological process that links diabetic macro- and
microvascular disease.
Studies conducted in humans observed that the infusion
of native GLP-1 in healthy volunteers improved the blood
flow in the forearm induced by the secretion of acetylcholine,
as measured by plethysmography. In fasting T2DM subjects
with stable coronary artery disease (n = 12), a notable
improvement was found in endothelial function after the
infusion of GLP-1, as demonstrated by an increase in flow-
mediated vasodilation of the brachial artery during a hyper-
insulinaemic clamp. Similarly, in an observational study of
20 diabetic subjects receiving metformin, exenatide treat-
ment (twice daily) for 16 weeks improved flow-mediated
vasodilation of the brachial artery after 5 minutes of ischae-
mia, as determined by ultrasound, compared with patients
receiving glimepiride [13].
It is unclear whether the beneficial endothelial effects that
are attributed to native GLP-1 are mediated by an endothelial
GLP-1R. Many of these studies do not control for the effects
of GLP-1 on increasing insulin secretion and decreasing
glucose, so the improvement in endothelial function could
be by indirect mechanisms.
The intra-arterial infusion of GLP-1 in obese subjects
with metabolic syndrome improved acetylcholine- and
sodium nitroprusside-induced forearm blood flow only in
the presence of an intra-arterial infusion of insulin. In
contrast, infusion of GLP-1 into the femoral artery after fast-
ing in healthy subjects improved the flow, independently of
insulin. Moreover, GLP-1 promotes vasodilation of isolated
mesenteric arteries in the absence of insulin in a nitric oxide
synthase-dependent manner.
Liraglutide attenuates induction of plasminogen activa-
tor inhibitor type-1 (PAI-1) and vascular adhesion mole-
cule (VAM) expression in human vascular endothelial
cells (hVECs) in vitro. Therefore, it may protect against
endothelial dysfunction, an early abnormality in vascular
disease in diabetic patients. In vitro studies demonstrated
GLP-1R-mediated inhibition of PAI-1 and VAM expres-
sion. Liraglutide treatment also increased nitric oxide syn-
thase (eNOS) activity and reduced intercellular adhesion
molecule (ICAM-1) expression in the aortic endothelium,
another GLP-1R-dependent effect. All these studies there-
fore identify a potential molecular mechanism of protec-
tion by GLP-1R-mediated liraglutide against endothelial
dysfunction [53].
Further studies are required to evaluate the direct and
indirect actions of the GLP-1 RAs against native GLP-1 on
endothelial function or vascular smooth muscle cells in dia-
betic and nondiabetic subjects. They should specify whether
part or all the observed effects attributed to GLP-1 are medi-
ated by GLP-1R, GLP-1 (9-36) or degradation products that
exert vasodilatory effects independent of GLP-1R function.
6.2. Glp-1 Ras and Coronary Ischaemia. A great many pre-
clinical and clinical studies show that the GLP-1 RAs have
a cardioprotective effect. Nevertheless, many of these do
not distinguish whether the mechanism by which this
effect occurs is direct, through the GLP-1R, indirect via
other pathways, or whether they could be potential effects
of GLP-1 (9-36).
A beneficial effect of the infusion of GLP-1 (for 72 hours)
has been observed in patients with acute myocardial infarc-
tion (AMI) and left ventricular dysfunction after reperfusion,
with improved ejection fraction and ventricular wall motion.
Acute infusion of GLP-1, 30 minutes before a dobutamine
stress cardiac ultrasound and 30 minutes afterwards pre-
vented the development of postischaemic myocardial dys-
function [13].
Lønborg et al. investigated the effects of a 6-hour infusion
of exenatide compared with placebo during the 15 minutes
prior to reperfusion in patients about to undergo a coronary
intervention to treat ST-segment elevation myocardial
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infarction (STEMI). Exenatide was effective in reducing the
size of the infarct in relation to the ischaemic area and
increased the myocardial salvage index measured by cardiac
magnetic resonance 90 days postinfusion. In contrast,
patients treated with exenatide had no reduction in mortality
or improvement in left ventricular contractility. Post hoc
analyses revealed that a trend towards a smaller final infarct
size in patients treated with exenatide versus placebo (13± 9
versus 17± 14 g; p = 0 11). This cardioprotection described
with exenatide was observed in both diabetic and nondiabetic
patients [54]. Complementary evidence of the cardioprotec-
tive effect of exenatide was obtained in a study that included
58 patients with STEMI and thrombolysis. Compared to
placebo, the exenatide group showed an improvement in left
ventricular function at 6 months and a reduction in the
infarct size at one month [55].
Liraglutide also demonstrated cardioprotection in a trial
with 96 patients with STEMI who underwent percutaneous
coronary angioplasty. Liraglutide treatment (0.6mg for two
days, 1.2mg for two days and 1.8mg for three days) was
compared with placebo, finding a better myocardial salvage
index in the liraglutide treatment arm (0.66± 0.14 versus
0.55± 0.15; p = 0 001), smaller infarct size (15± 12 versus
21± 15; p = 0 05), and lower high-sensitivity C-reactive
protein levels [56].
Thus, native GLP-1 and GLP-1 RAs together produce
favourable effects in patients with coronary artery disease,
which were initially attributed to direct effects on the
myocardium. New findings that call into question GLP-
1R expression in the ventricular cardiomyocytes support
the hypothesis that this beneficial effect on the myocar-
dium could be mediated by a process independent of the
GLP-1R [13].
6.3. Glp-1 Ras and Heart Failure. Promising experimental
studies in animal models have generated high expectations
of the possible benefit of GLP-1 RAs in patients with
T2DM and heart failure. Until the moment, there are no pub-
lished studies in which the effect on heart failure of GLP 1
agonists is the primary objective. Hospital admissions due
to heart failure have been explored as secondary objectives.
However, there are several clinical trials (http://www
.clinicaltrials.gov) completed and pending for publication
which explore this, such as functional impact of GLP-1 for
heart failure treatment (FIGHT), liraglutide and heart failure
in type 2 diabetes, evaluating the use of exenatide in people
with type 2 diabetes and diastolic heart failure, incretin-
based drugs and the risk of heart failure, effects of exenatide
in type 2 diabetic patients with congestive heart failure, and
PROCLAIM: effect of AC2592 administered by continuous
subcutaneous infusion in subjects with advanced congestive
heart failure.
Meta-analyses of phase II/III clinical trials of exenatide,
liraglutide, albiglutide, and dulaglutide have shown that they
do not increase the risk of hospitalization for heart failure,
confirming the findings of cardiovascular safety trials, which
we will review later. The Liraglutide Effect and Action in Dia-
betes: Evaluation of Cardiovascular Outcome Results
(LEADER) trial, in particular, showed a significant 12%
reduction in the expanded composite outcome comprising
the primary endpoint plus coronary revascularizations and
hospitalizations for angina and heart failure. However, there
was no significant benefit on heart failure admissions [57].
For the moment, clinical data have demonstrated a neutral
effect on the incidence of hospitalization for heart failure;
nevertheless, this has to be explored as a primary objective
in future trials.
7. Current Situation: Cardiovascular Outcome
Trials (Cvots) on Glp-1 Receptor Agonists
As mentioned above, as of 2008, specific studies must be con-
ducted in all new drugs for the treatment of T2DM to dem-
onstrate their cardiovascular safety. These are performed in
order to prove noninferiority as regards the appearance of
MACE (major adverse cardiovascular events) with antidia-
betic drugs. A multitude of studies has been performed aimed
at demonstrating this noninferiority: TECOS, SAVOR TIMI
53, EXAMINE, ELIXA, EMPA-REG, LEADER, SUSTAIN-6,
CANVAS, and EXSCEL (Table 2). Next, we will discuss those
that were carried out with GLP-1 receptor analogues: ELIXA,
LEADER, SUSTAIN-6, and EXSCEL [58].
7.1. ELIXA Study. The ELIXA study (evaluation of lixisena-
tide in acute coronary syndrome) was the first safety study
carried out on GLP-1 RAs and was published in December
2015. A total of 6068 patients were included, randomised to
treatment with lixisenatide 10μg daily (which could be
increased to 20μg at the investigator’s discretion) or placebo.
The aim of the study was to demonstrate the noninferiority
of lixisenatide compared with placebo, both with the stan-
dard treatment that they required, on the development of
MACE. The primary endpoint was the time to occurrence
of any of the following events: death from cardiovascular
causes, nonfatal myocardial infarction, nonfatal stroke, or
hospitalisation for unstable angina. Other secondary end-
points were a composite of the primary endpoint or hospita-
lisation for heart failure and a composite of the primary
endpoint and hospitalisation for heart failure or coronary
revascularisation procedures.
The patients included in this trial were all patients with
T2DM who had a myocardial infarction or who had been
hospitalized for unstable angina within the previous 180 days
(secondary prevention). Mean follow-up was 25 months in
each group.
With respect to the primary endpoint results, lixisenatide
showed noninferiority to placebo (hazard ratio [HR]=1.02;
95% confidence interval [CI], 0.89–1.17; p < 0 001) but not
superiority (p = 0 81). Analysing the different components
separately, the number of deaths from cardiovascular causes
(p = 0 85), nonfatal myocardial infarction (p = 0 71), nonfa-
tal stroke (p = 0 54), and hospitalisation for unstable angina
(p = 0 81) was also similar in both groups. The same occurred
with hospitalization for heart failure (p = 0 75), coronary
revascularisation, and death from any cause.
Within other CVRFs, a modest but significant between-
group difference in the change in body weight from baseline
was apparent at 12 weeks (−0.6 kg in the lixisenatide group












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7Journal of Diabetes Research
versus −0.0 kg in the placebo group, p < 0 001). This rela-
tive weight difference was sustained throughout the
follow-up period. A modest relative difference (lixisenatide
minus placebo) in systolic blood pressure in the lixisena-
tide group as compared with the placebo group was
sustained throughout follow-up, with an average difference
across all visits of −0.8mmHg (95% CI, −1.3 to −0.3) in
favor of lixisenatide (p = 0 001).
Thus, lixisenatide showed a neutral cardiovascular profile
in patients with type 2 diabetes and a recent acute coronary
syndrome [59].
7.2. LEADER Study. The LEADER trial, published in July
2016, was conducted to study the cardiovascular effect of
liraglutide when added to standard treatment for T2DM.
The study included 9340 patients who were randomised to
treatment with liraglutide (up to a maximum dose of
1.8mg/day) or placebo. The primary composite outcome
was the time to occurrence of the first MACE: death from
cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke. Secondary outcomes included the time to
occurrence of the first event: expanded composite cardiovas-
cular outcome (death from cardiovascular causes, nonfatal
myocardial infarction, nonfatal stroke, coronary revasculari-
sation, hospitalisation for unstable angina, or hospitalisation
for heart failure), death from any cause, and each of the
individual components of the expanded composite cardio-
vascular outcome.
Mean follow-up was 3.8 years. Individuals included
were either patients with high cardiovascular risk (>50
years with established CVD) or >60 years with at least
one CVRF. With these criteria, approximately 80% of all
the patients included had a history of CVD and was,
therefore, on secondary prevention, and 20% was on
primary prevention.
With respect to primary outcomes, the liraglutide
group had a statistically significant lower risk of MACE
compared with placebo (HR=0.87; 95% CI, 0.78–0.97).
With respect to deaths from cardiovascular causes, the risk
was also lower in the liraglutide group (HR=0.78; 95% CI,
0.66–0.93 p = 0 007). The risk of death from any cause was
also lower in the liraglutide group (HR=0.85; 95% CI,
0.74–0.97; p = 0 02), as was the risk of nonfatal myocardial
infarction and nonfatal stroke, but the results were not
statistically significant.
Analysis of the secondary composite outcome of micro-
vascular complications (nephropathy and retinopathy)
showed that the liraglutide group had lower risk (HR=0.84;
95% CI, 0.73–0.97; p = 0 02). In terms of nephropathy alone,
there was also lower risk in the liraglutide group (HR=0.78;
95% CI, 0.67–0.92; p = 0 003), although the risk of retinopa-
thy (HR=1.15; 95% CI, 0.87–1.52; p = 0 33) rose slightly but
not significantly, in the liraglutide group (probably related to
better early glycaemic control).
Significant differences were also observed as regards
other CVRFs between the group treated with liraglutide
and the placebo group. Weight loss was −2.3 kg greater in
the liraglutide group, together with a greater decrease in
SBP (−1.2mmHg) and DBP (−0.6mmHg). The liraglutide
group showed a mean increase in heart rate of 3 bpm.
In this trial, patients on treatment with liraglutide had
a lower risk of presenting the primary outcome and a
lower risk of cardiovascular death and death from any
cause and microvascular complications, demonstrating
superiority in terms of cardiovascular safety. The number
of patients needed to treat (NNT) to prevent an episode
in 3 years was 66 for the primary outcome and 98 for
death from any cause [60].
7.3. SUSTAIN-6. The SUSTAIN-6 trial (cardiovascular and
other long-term outcomes with semaglutide in subjects
with type 2 diabetes) was conducted to determine the car-
diovascular safety of semaglutide compared to placebo,
both in the presence of standard treatment, and was pub-
lished in September 2016. Semaglutide is a new GLP-1 RA
that has still not been approved for the treatment of
T2DM; it has a long half-life (6-7 days), which enables
weekly subcutaneous administration.
SUSTAIN-6 was a randomised, double-blind, placebo-
controlled trial. It included 3297 patients who were rando-
mised 1 : 1 : 1 : 1 to treatment with semaglutide 0.5mg,
semaglutide 1mg, or placebo (two doses similar to those
of the semaglutide treatment).
The primary composite outcome was the time to occur-
rence of the first MACE: death from cardiovascular causes,
nonfatal myocardial infarction, or nonfatal stroke. Secondary
outcomes included the time to occurrence of the first event:
expanded composite cardiovascular outcome (death from
cardiovascular causes, nonfatal myocardial infarction, nonfa-
tal stroke, coronary revascularisation, hospitalisation for
unstable angina, or hospitalisation for heart failure) and
death from any cause and each of the individual components
of the expanded composite cardiovascular outcome. Retinop-
athy and follow-up of nephropathy were also assessed.
As in the LEADER trial, patients included in SUSTAIN-6
were patients with very high cardiovascular risks who were
≥50 years old with established CVD (coronary heart disease,
cerebrovascular disease, peripheral vascular disease, chronic
kidney disease stage III or greater, or heart failure NYHA
class II or III) or ≥60 years old with at least one CVRF. Mean
follow-up was 2.1 years. Of the 3297 patients, 2735 (83.0%)
had established cardiovascular disease (including chronic
kidney disease of stage 3 or higher), 1940 patients (58.8%)
had established cardiovascular disease without chronic kid-
ney disease, 353 (10.7%) had chronic kidney disease only,
and 442 (13.4%) had both cardiovascular disease and kidney
disease; 17% of the patients had cardiovascular risk factors
and was 60 years of age or older.
With respect to the primary outcome results of the
semaglutide group, the first cardiovascular episode pre-
sented on 108 occasions (1648 patients; 6.6% of them
with at least one episode) compared to 146 episodes in
the placebo group (1649 patients; 8%), which implies a
HR=0.74 (95% CI, 0.58–0.95), p < 0 001 for noninferior-
ity and p = 0 02 for superiority. The first episode of non-
fatal myocardial infarction occurred on 47 occasions in
the semaglutide group and in 64 in the placebo group:
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HR=0.74 (95% CI, 0.51–1.08; p = 0 12), a difference that
was not significant. With respect to nonfatal stroke, the
semaglutide group presented 27 episodes compared with
44 in the placebo group: HR=0.61 (95% CI, 0.38–0.99;
p = 0 04). The risk of cardiovascular death was similar in
both groups (p = 0 92), nor were differences observed in
death from any other cause (p = 0 79).
Significant differences were also observed as regards
other CVRFs between the group treated with semaglutide
and the placebo group. The semaglutide group presented
a reduction in HbA1c of −1.1% in patients who received
the 0.5mg dose and− 1.4% in those treated with the 1mg
dose, both with significant differences with the placebo
group (p < 0 001). During the trial, the use of antidiabetic
medication in the placebo group was much greater than in
the semaglutide group, and they tended to take insulin more
than twice as frequently. Weight loss was −3.6 kg greater in
the semaglutide 0.5mg group and − 4.9 kg in the semaglutide
1mg group. In the placebo group, weight losses of −0.7 kg
and− 0.5 kg were observed, respectively. Compared to the
placebo group, the weight loss in the semaglutide group
was 2.9 kg in those who received doses of 0.5mg and 4.3 kg
in those who received 1mg (p < 0 001). The semaglutide
group also presented a decrease in SBP of −1.3mmHg
(0.5mg) and− 2.6mmHg (1mg), compared with placebo
(p < 0 001). As with liraglutide, the semaglutide group
showed an increase in heart rate with respect to placebo
of 2 bpm (0.5mg group) and 2.5 bpm (1mg) (p < 0 001).
Fifty diabetic retinopathy complications occurred in the
semaglutide arm and 29 in the placebo arm (HR=1.76;
95% CI, 1.11–2.78; p = 0 02). These differences were observed
early in the trial. With respect to retinopathy treatments,
photocoagulation was required on 38 occasions in the sema-
glutide group versus 20 in the placebo group and intravitreal
agents on 16 occasions with semaglutide versus 13 with
placebo. Complications such as vitreous haemorrhage
occurred on 16 occasions (semaglutide) versus 7 (placebo),
while 5 (semaglutide) patients versus 1 (placebo) developed
diabetes-related blindness. Of the 79 patients with retinopa-
thy complications, 66 (83.5%) had preexisting retinopathy
(42 of 50 in the semaglutide group [84%], and 24 of 29
in the placebo group [82.8%]) [61, 62]. Worsening of
retinopathy was related to the presence of retinopathy at
the start of the study, poor baseline metabolic control
and with greater reductions in HbA1c in the first 16 weeks
of the trial [63].
As regards the appearance of new nephropathy or
worsening of existing nephropathy, there were 62 episodes
in the semaglutide arm and 100 in the placebo group
(HR=0.64; 95% CI, 0.46–0.88; p = 0 005).
In this trial, patients on semaglutide treatment had a 26%
lower risk of developing the primary outcome. This lower
risk is attributed above all to the significantly lower risk of
developing nonfatal stroke (39%) and a nonsignificant
reduction in the risk of developing a nonfatal myocardial
infarction (26%), since no differences were observed as
regards cardiovascular death. The NNT to avoid this primary
event would be 45 for 24 months. Thus, semaglutide shows
superiority as regards cardiovascular safety [64].
7.4. EXSCEL. The EXSCEL trial (exenatide study of
cardiovascular event lowering), published in September
2017, was conducted to demonstrate the cardiovascular
safety of extended-release exenatide versus placebo,
both administered with standard treatment. This study
included the largest number of patients with T2DM
among the cardiovascular safety studies conducted with
GLP-1 RAs (more than 14,752 patients, in 687 centres
in 35 countries) with a wide variety of cardiovascular
situations. Patients were randomly assigned in a 1 : 1
ratio to receive subcutaneous injections of extended-
release exenatide at a dose of 2mg or matching placebo
once weekly.
The primary outcome was defined as the first occurrence
of any component of the composite outcome of death from
cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke (three-component MACE outcome), in a
time-to-event analysis. Secondary outcomes included death
from any cause, death from cardiovascular causes, and the
first occurrence of nonfatal or fatal myocardial infarction,
nonfatal or fatal stroke, hospitalization for acute coronary
syndrome, and hospitalization for heart failure, in time-to-
event analyses.
The trial was designed such that approximately 70% of
enrolled patients would have had previous cardiovascular
events, and 30% would not have had previous cardiovascular
events. Of the 14,752 patients (of whom 10,782), 73.1% had
previous cardiovascular disease. The median duration of
follow-up was 3.2 years.
Weekly exenatide did not increase the incidence of the
first episode of MACE (death from cardiovascular causes,
nonfatal myocardial infarction, and nonfatal stroke) com-
pared to placebo (HR=0.91; 95% CI, 0.83–1.00; p < 0 001
for noninferiority). Fewer episodes were observed with
exenatide (839; 11.4%) than with placebo (905; 12.2%),
but statistical significance was not reached to demonstrate
superiority (p = 0 061). The rates of the first fatal or non-
fatal myocardial infarction, fatal or nonfatal stroke, and
other secondary outcomes did not differ significantly
between the two groups. Additionally, in a prespecified
secondary analysis, patients treated with weekly exenatide
had a 14% lower incidence of death from all causes compared
to placebo (HR=0.86; 95% CI, 0.77–0.97). Therefore, the
incidence of MACE did not differ between weekly exenatide
and placebo [65].
Within other CVRFs, the mean glycated hemoglobin
level was 0.7 percentage points lower in the exenatide
group than in the placebo group (95% confidence interval
[CI], −0.7 to −0.6). Overall, least-square mean values were
also lower with exenatide than with placebo with respect
to body weight (difference of −1.27 kg), systolic blood
pressure (−1.57mmHg), low-density lipoprotein choles-
terol (−1.5mg per deciliter [−0.04mmol per liter]), and
triglycerides (−1.8mg per deciliter [−0.02mmol per liter]);
values were higher in the exenatide group than in the
placebo group with respect to diastolic blood pressure
(difference of 0.25mmHg).
To conclude, once-weekly administration of extended-
release exenatide in patients with type 2 diabetes at a wide
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range of cardiovascular risk appeared not to cause an
increase in their overall cardiovascular risk.
CV safety trials conducted to meet the FDA guidance
generally use an efficient trial design that enrolls patients
with more advanced atherosclerotic CV risk or established
CVD to accrue sufficient events in a timely manner. How-
ever, a major limitation of such an approach is that the safety
population is not representative of patients in ambulatory
diabetes care, thereby raising questions about generalizabil-
ity. Differences in baseline characteristics of the patient
population recruited as well as in trial design and protocol
make it difficult to compare results from these trials and
inappropriate to reliably assess relative benefits of therapies.
Another notable finding is that the favorable CV
outcome benefit observed in LEADER and SUSTAIN-6
contrasts with the null results seen with other GLP-1
RA, lixisenatide, and ELIXA trial, which enrolled patients
within 180 days of acute coronary syndrome or EXSCEL
trial. Although the exact reasons are not clear, this
discrepancy might be related to differences in pharmacoki-
netic and pharmacodynamic properties. Another explana-
tion for the contrasting results might be the trial differences
in the enrollment of lower-risk versus higher-risk patients
and between the time of follow-up.
8. Conclusions
Recent clinical trials aimed at studying cardiovascular epi-
sodes associated with the use of antidiabetics have increased
our understanding of the potential effects of drugs for
T2DM on cardiovascular risk. Clinical trials conducted with
GLP-1 RAs and CVOTs present considerable differences in
design and enrolment which limits comparisons among
them. Liraglutide and semaglutide showed superiority in
cardiovascular benefit compared with placebo, both in the
presence of standard treatment. Lixisenatide and extended-
release exenatide were neutral, that is, they are safe from a
cardiovascular point of view, but for the moment they have
not demonstrated to provide any benefit.
Although many of the mechanisms by which liraglutide
and semaglutide produce a cardiovascular benefit are still
unknown (the antiatherosclerotic action hypothesis is pre-
vailing), it would be desirable for these benefits to be incorpo-
rated into the therapeutic algorithms routinely used in
clinical practice.
Since cardiovascular disease continues to be the leading
cause of death in patients with T2DM, the prevention of car-
diovascular complications and the cardiovascular safety of
the treatment in individuals who have already developed a
cardiovascular episode should be a primary objective when
selecting treatment for our patients.
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